Fellowship · Indianapolis, IN
Sponsored by Indiana University School of Medicine · Director Sharon Robertson
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
The New England journal of medicine · 2023 · 703 citations · Lisa Landrum
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
The New England journal of medicine · 2023 · 633 citations · Lisa Landrum
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 127 citations · Sharon Robertson
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 55 citations · Lisa Landrum
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
Nature medicine · 2025 · 59 citations · Lisa Landrum
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 109 citations · Lisa Landrum
Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 25 citations · Lisa Landrum
Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278).
Gynecologic oncology · 2025 · 17 citations · Sharon Robertson